March 19, 2008-Strides Arcolab, one of India's largest exporters of branded generic pharmaceutical products, today announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10ml vials.
The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE: STAR, BSE: 532531]
Fosphenytoin is the third approval amongst 22 sterile submissions the Company has submitted with US FDA.
Mr.Arun Kumar - Vice Chairman and Group CEO of Strides Arcolab stated: "We are excited with our third sterile injecatable approval and are delighted having achieved a key milestone in creating a global sterile injectable business"
No comments:
Post a Comment